Cellectis (CLLS) Operating Margin (2015 - 2026)
Cellectis' (CLLS) quarterly Operating Margin came in at 435.64% in Q1 2026, down 30257.0% year-on-year from N/an in Q1 2025, and down 219.25% quarter-over-quarter from 136.46% in Q4 2025.
Cellectis (CLLS) Operating Margin (2015 - 2026) Analysis & Trends
Cellectis' Operating Margin history runs 12 years deep, the most recent figure standing at 435.64% for Q1 2026.
- On a quarterly basis, Operating Margin fell 30257.0% year-over-year to 435.64% in Q1 2026; TTM through Mar 2026 was 62.6%, a 4833.0% increase from a year earlier, with the FY2025 full-year figure at 81.64%, up 6185.0% from the prior year.
- Operating Margin fell to 435.64% in Q1 2026 per CLLS's latest filing, from 136.46% in the prior quarter.
- Across five years, Operating Margin topped out at 22.86% in Q3 2025 and bottomed at 16856.83% in Q1 2023.
- The 5-year median for Operating Margin is 435.64% (2026), against an average of 4411.23%.
- Across the five-year window, Operating Margin slumped 1512056 bps in 2022 and surged 1639539 bps in 2024, its largest moves.
- Year by year, Operating Margin stood at 35.32% in 2022, then slumped by 29490 bps to 10451.94% in 2023, then soared by 99 bps to 83.99% in 2024, then plunged by 62 bps to 136.46% in 2025, then slumped by 219 bps to 435.64% in 2026.
- Per Business Quant, the three latest CLLS Operating Margin figures stand at 435.64% (Q1 2026), 136.46% (Q4 2025), and 22.86% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -435.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -435.64% |
| Dec 31, 2025 | -136.46% |
| Sep 30, 2025 | 22.86% |
| Jun 30, 2025 | -57.32% |
| Mar 31, 2025 | -133.07% |
| Dec 31, 2024 | -83.99% |
| Sep 30, 2024 | -66.48% |
| Jun 30, 2024 | -213.51% |
| Mar 31, 2024 | -461.44% |
| Dec 31, 2023 | -10,451.94% |
| Sep 30, 2023 | -13,336.13% |
| Jun 30, 2023 | -13,270.22% |
| Mar 31, 2023 | -16,856.83% |
| Dec 31, 2022 | -35.32% |
| Sep 30, 2022 | -15,630.29% |
| Jun 30, 2022 | -2,089.75% |
| Mar 31, 2022 | -1,755.44% |
| Dec 31, 2021 | -239.33% |
| Sep 30, 2021 | -509.72% |
| Jun 30, 2021 | -335.37% |